share_log

Novavax | 8-K: Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights

Novavax | 8-K: Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights

諾瓦瓦克斯醫藥 | 8-K：Novavax 公佈2024年第二季度財務業績和運營亮點
美股SEC公告 ·  08/08 08:09
Moomoo AI 已提取核心訊息
On August 8, 2024, Novavax, Inc. reported its financial results for the second quarter ended June 30, 2024. The company announced total revenue of $415 million for the quarter and ended the period with $1.1 billion in cash. Novavax has filed for authorization of its updated 2024-2025 COVID-19 vaccine with the U.S. FDA and EMA and has received a significant upfront payment and equity investment from Sanofi as part of a collaboration agreement. The company is also preparing for Phase 3 trials for its COVID-19-Influenza Combination and standalone influenza vaccines, expected to begin in Q4 2024. Novavax has implemented a cost reduction program, resulting in a 34% reduction in combined R&D and SG&A expenses compared to the same period in 2023. The company expects to deliver its updated COVID-19 vaccine by the start of the 2024-2025 vaccination season and has submitted an EUA amendment to the FDA. Novavax's financial guidance for the full year 2024 reflects total revenue between $700 million and $800 million, with combined R&D and SG&A expenses remaining between $700 million and $750 million.
On August 8, 2024, Novavax, Inc. reported its financial results for the second quarter ended June 30, 2024. The company announced total revenue of $415 million for the quarter and ended the period with $1.1 billion in cash. Novavax has filed for authorization of its updated 2024-2025 COVID-19 vaccine with the U.S. FDA and EMA and has received a significant upfront payment and equity investment from Sanofi as part of a collaboration agreement. The company is also preparing for Phase 3 trials for its COVID-19-Influenza Combination and standalone influenza vaccines, expected to begin in Q4 2024. Novavax has implemented a cost reduction program, resulting in a 34% reduction in combined R&D and SG&A expenses compared to the same period in 2023. The company expects to deliver its updated COVID-19 vaccine by the start of the 2024-2025 vaccination season and has submitted an EUA amendment to the FDA. Novavax's financial guidance for the full year 2024 reflects total revenue between $700 million and $800 million, with combined R&D and SG&A expenses remaining between $700 million and $750 million.
2024年8月8日，諾瓦瓦克斯醫藥公司公佈了截至2024年6月30日第二季度的財務業績。該公司宣佈本季度總營業收入爲4.15億美元，並以11億美元的現金結算了本期。諾瓦瓦克斯醫藥公司已向美國 FDA 和歐洲藥品管理局申請其2024-2025年更新的 COVID-19 生物-疫苗的授權，並已收到賽諾菲安萬特的巨額預付款和股權投資，作爲合作協議的一部分。該公司還準備在2024年第四季度開始進行其COVID-19流感聯合疫苗和獨立流感疫苗的第三階段試驗。諾瓦瓦克斯醫藥公司實施了成本減少計劃，與2023年同期相比，研發費用和銷售費用合計減少了34%。該公司預計在2024-2025年疫苗接種季節開始時交付更新的 COVID-19 生物-疫苗並向美國 FDA 提交緊急使用授權修正案。諾瓦瓦克斯醫藥公司2024年全年的財務指導反映了總營業收入在7000萬美元至8000萬美元之間，研發費用和銷售費用合計仍在7000萬美元至7500萬美元之間。
2024年8月8日，諾瓦瓦克斯醫藥公司公佈了截至2024年6月30日第二季度的財務業績。該公司宣佈本季度總營業收入爲4.15億美元，並以11億美元的現金結算了本期。諾瓦瓦克斯醫藥公司已向美國 FDA 和歐洲藥品管理局申請其2024-2025年更新的 COVID-19 生物-疫苗的授權，並已收到賽諾菲安萬特的巨額預付款和股權投資，作爲合作協議的一部分。該公司還準備在2024年第四季度開始進行其COVID-19流感聯合疫苗和獨立流感疫苗的第三階段試驗。諾瓦瓦克斯醫藥公司實施了成本減少計劃，與2023年同期相比，研發費用和銷售費用合計減少了34%。該公司預計在2024-2025年疫苗接種季節開始時交付更新的 COVID-19 生物-疫苗並向美國 FDA 提交緊急使用授權修正案。諾瓦瓦克斯醫藥公司2024年全年的財務指導反映了總營業收入在7000萬美元至8000萬美元之間，研發費用和銷售費用合計仍在7000萬美元至7500萬美元之間。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息